Dr. Greg Sullivan
Chief Scientific Officer and Chief Executive Officer
Greg Sullivan, MD, who co-founded Bridge Therapeutics with the goal of helping patients beyond the walls of his own medical practice, has 25 years of experience conducting human studies for new drugs. Since 2003, he has performed numerous buprenorphine studies, including FDA safety and efficacy studies for every buprenorphine product currently approved for the U.S. market. He is board-certified in both addiction medicine and internal medicine and treats chronic pain patients at his practice in Birmingham, Ala.
Alton S. Kelley
President and Head of Business Development
Mr. Kelley has worked in the pharmacy, marketing and business development space throughout his career. Mr. Kelley has a B.B.A. from the University of Alabama with a Major in Business Management and a Minor in Computer Science.
Chief Financial Officer
Mr. Mullin has over 20 years of experience in finance restructuring consulting and asset management. He is the founder of Joseph E. Mullin LLC, where he has worked on projects for a variety of companies in the retail, energy and media space. He previously worked at Millennium Global, Invesco, WL Ross and Goldman Sachs. He has an AB from Harvard College.